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Abstract
The mechanism of latent tuberculosis (TB) infection remains elusive. Several host factors that are involved in this complex
process were previously identified. Micro RNAs (miRNAs) are endogenous ,22 nt RNAs that play important regulatory roles
in a wide range of biological processes. Several studies demonstrated the clinical usefulness of miRNAs as diagnostic or
prognostic biomarkers in various malignancies and in a few nonmalignant diseases. To study the role of miRNAs in the
transition from latent to active TB and to discover candidate biomarkers of this transition, we used human miRNA
microarrays to probe the transcriptome of peripheral blood mononuclear cells (PBMCs) in patients with active TB, latent TB
infection (LTBI), and healthy controls. Using the software package BRB Array Tools for data analyses, 17 miRNAs were
differentially expressed between the three groups (P,0.01). Hierarchical clustering of the 17 miRNAs expression profiles
showed that individuals with active TB clustered independently of individuals with LTBI or from healthy controls. Using the
predicted target genes and previously published genome-wide transcriptional profiles, we constructed the regulatory
networks of miRNAs that were differentially expressed between active TB and LTBI. The regulatory network revealed that
several miRNAs, with previously established functions in hematopoietic cell differentiation and their target genes may be
involved in the transition from latent to active TB. These results increase the understanding of the molecular basis of LTBI
and confirm that some miRNAs may control gene expression of pathways that are important for the pathogenesis of this
infectious disease.
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Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB),
remains a threat to global health. In 2008, TB accounted for
nearly 1.8 million deaths worldwide, second only to the human
immunodeficiency virus (HIV) as an infectious cause of death [1].
Approximately ,5 to 10% of MTB-infected individuals develop
active TB at some stage in their life [2]. The remaining ,90 to
95% infected people remain asymptomatic, carrying so-called
latent TB infection (LTBI), which is defined solely by the evidence
of immunological sensitization to mycobacterial proteins (MTB-
purified protein derivative, PPD) in the absence of clinical signs
and symptoms of active disease [3]. The World Health
Organization estimates that nearly one third of the world
population is PPD+ [4]. This vast reservoir of LTBI-infected
individuals is a constant source of disease caused by reactivation,
especially in developing countries with large numbers of TB cases
and a high TB incidence rate. The risk of TB reactivation among
immunocompetent LTBI persons is estimated as 10% per lifetime.
Impaired immunity such as HIV infection increases the risk to
10% per year and ,50% per lifetime [5,6].
The exact underlying mechanisms of LTBI and its transition to
active TB remain elusive. LTBI rely on an equilibrium in which
the host is able to control the infection but does not completely
eradicate the bacteria [7]. Latency may depend upon the virulence
of the MTB strain [8] and upon the host immune response. Some
bacteria may escape attack from the innate or acquired immune
system by blunting phagosome and lysosome fusion, nitric oxide
production, antigen presentation, or other bactericidal processes
from the host, and therefore survive in a phenotype called
dormancy [9]. Immunosuppressants such as HIV infection or anti-
tumor necrosis factor (TNF) treatment for rheumatoid arthritis
may lead to the reactivation of these bacteria. Owing to the lack of
a widely accepted animal model to study the pathogenesis of M.
tuberculosis, population-based studies have been the best methods to
reveal the complex biology of LTBI. Earlier studies which used
whole-genome transcriptional profiling of peripheral blood
mononuclear cells (PBMCs) [10] or whole blood cells [11] to
characterize signatures of susceptibility or resistance to tubercu-
losis, described FcGR1B (CD64) as the most deregulated gene in
individuals with active TB in Caucasian populations and African
populations in which TB was highly endemic. Another study
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driven interferon (IFN)-inducible genes correlated with radiolog-
ical extent of active TB and reverted to that of healthy controls
after treatment [12]. By using intracellular flow cytometry staining
of stimulated PBMCs with MTB-derived peptides, a recent report
found a dominant TNF-a+ MTB–specific CD4+ T cell response
that discriminated between latent infection and active disease [13].
Although these studies further our understanding of the funda-
mental biology of TB and offer leads for diagnosis and treatment
options in the future, taken together they do not fully explain how
the pathogen transitions from the latent stage to active TB.
MicroRNAs (miRNAs) are endogenous ,22-nucleotide RNAs
that play important regulatory roles in animals and plants by
targeting mRNAs for cleavage or translational repression [14].
There are currently ,1,000 human miRNAs sequences listed in
the miRNA registry which may target about 60% of all
mammalian genes [http://www.mirbase.org/], indicating that
these small molecules play fundamental and global functions in
human biology, including development [15], differentiation [16],
apoptosis [17], metabolism [18], viral infection [19], and cancer
[20]. MiRNAs also modulate the innate and adaptive immune
responses to pathogens by affecting mammalian immune cell
differentiation and the development of diseases of immunological
origin [21,22].The clinical application of miRNAs as diagnostic or
prognostic biomarkers has already been demonstrated in various
types of cancers [23,24]. However, compared to their well-known
role in cancer, the role of miRNAs in susceptibility and resistance
to infectious disease, especially those of bacterial origin, is still
poorly understood.
In the present study, we compared the miRNA expression
profiles of PBMCs from patients with active TB, subjects with
LTBI, and healthy controls in order to test the hypothesis that
candidate miRNAs regulate the transition from LTBI to active
TB. We used a miRNA microarray chip containing ,960 probes
to identify the differently expressed miRNAs, and performed real-
time quantitative polymerase chain reaction (qPCR) for confir-
mation. The putative regulatory network of miRNAs that were
differentially expressed in the samples from active TB and LTBI
individuals was constructed based on predicted target genes and
previously published genome-wide transcriptional profiles. Our
study provides a greater understanding of the role of miRNAs-
mediated regulated networks in the transition from latent to active
TB.
Results
Expression profiles of miRNAs in PBMC from different
groups
We first determined whether the miRNA profile of patients with
active TB was distinct from that of patients with LTBI and healthy
controls. The demographic and clinical characteristics of all
patients with active TB, LTBI, and the healthy controls are
summarized in Table 1.We used a human miRNA microarray to
perform the 955 miRNAs assay in PBMCs from 6 patients with
active TB, 6 donors with LTBI, and 3 healthy persons for a total of
15 random selected biologically independent samples (Table S1).
The microarray contains probes for 866 human and 89 human
viral miRNAs represented in the Sanger miRBase (release 12.0,
Table 1. Characteristics of study participants with active tuberculosis (TB), latent TB infection (LTBI) and healthy controls.
Active TB
Characteristic Pre-treatment Re-treatment Latent TB infection Healthy Controls
Total Number 28 1 29 18
Gender
Female 9 1 17 16
Male 19 0 12 2
Ethnicity
Han Chinese 28 1 29 18
Age, Mean Years 6 SEM 38.263.8 47 40.862.0 35.162.8
Diseases Characteristics
Pulmonary TB 26 1 Na Na
Lymph node TB 1 0 Na Na
Renal TB 1 0 Na Na
TST
Positive Na 29 3
Negative Na 0 15
IGRA
Positive 24 1 29 0
Negative 4 0 0 18
H I V --- -
HBV - - - -
HCV - - - -
Diabetes - - - -
NA, Not applicable; TST, Tuberculosis Skin Test; IGRA, Interferon-c Release Assay; TB, Tuberculosis; HIV, Human immunodeficiency virus; HBV, hepatitis B virus; HCV,
hepatitis C virus; SEM, standard error of the mean.
doi:10.1371/journal.pone.0025832.t001
miRNA Expression during M. tuberculosis Infection
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25832Sanger Institute, city, UK). Data analysis first consisted of
unsupervised analyses of miRNA signatures in the dataset without
a priori knowledge of the sample phenotypic classification [25].
After normalization and unsupervised filtering (see Materials and
Methods), the data yielded a list of 415 miRNAs. The expression
profiles of these 415 miRNAs were then subjected to unsupervised
hierarchical clustering using the Pearson correlation with average
linkage to create a condition tree (Fig. 1). The molecular
classification obtained through hierarchical clustering was then
compared with the phenotypic classification of the individuals
from whom the samples were obtained. Two branches were
obtained from the conditional tree that was generated: one branch
was composed of 3 patients with active TB, 2 subjects with LTBI,
and 2 healthy controls, while the other branch was composed of 3
patients with active TB, 4 subjects with LTBI, and 1 healthy
control. This result showed that there was no clear distinction
between the samples in regards to their clinical classification or age
and gender, which indicates a high variability of whole miRNA
profiles between individuals.
Subtle differences in gene expression among closely related
subtypes may escape detection when using unsupervised clustering
analysis. Therefore, we used BRB Arraytools to perform a F-test
comparison by supervised clustering in an attempt to identify
deregulated miRNAs between the different study groups [26]. We
first differentiated the 3 groups by using a supervised learning
algorithm to classify three or more groups (binary tree classifica-
tion). Expression profiles were first classified into group A (Active
TB) and group non-A (non-Active) (LTBI, Healthy) (node 1). The
non-A group was then classified into LTBI and Healthy (node 2).
Then, the same classification was used to generate node 3 (Healthy
and Non Healthy), node 4 (Active TB and LTBI), and node 5
(Latent and Non Latent), and node 6 (Active TB and Healthy). By
performing the 6 univariate tests (P,0.01) we identified a total of
38 miRNAs (Table S2 and Figure S1) that were statistically
different (P,0.01) in at least one comparison. Next, we used
Support vector machines (SMVs) as a prediction method to
capture the differently expressed miRNAs among the 3 groups
(Figure S1) [27]. Out of 10 miRNAs that differentiated node 1
(Active and Non Active) classification, 7 also differentiated node 4
(Active and LTBI) classification. These 7 miRNAs were then
marked as the differentially expressed miRNAs between Active TB
and LTBI. From the 6 univariate test results, a total of 17 miRNAs
(Table S3) were identified using this prediction method (P,0.01).
Among these 17 miRNAs, 7 miRNAs (hsa-miR-130b*, hsa-
miR-21*, hsa-miR-223, hsa-miR-302a, hsa-miR-424, hsa-miR-
451, hsa-miR-486-5p) were differentially expressed between active
TB and latent TB, 6 miRNAs were up-regulated in active TB
patients, and only hsa-miR-130b* showed reduced gene expres-
sion level. 7 miRNAs (hsa-miR-144,hsa-miR-133a,hsa-miR-365,
hsa-miR-424 ,hsa-miR-500, hsa-miR-661,hsa-miR-892b) had
different gene expression levels between active TB and healthy
controls; 4 of them (hsa-miR-144,hsa-miR-365 and hsa-miR-133a,
hsa-miR-424) were up-regulated and 3 of them (hsa-miR-500, hsa-
miR-661,hsa-miR-892b) were down-regulated in active TB
patients. Five miRNAs (hsa-miR-130a*, hsa-miR-296-5p, hsa-
miR-493*, hsa-miR-520d-3p, hsa-miR-661) had different expres-
sion levels between latent TB and healthy controls; all of them
except hsa-miR-296-5p were up-regulated in healthy controls.
Only hsa-miR-424 was up-regulated in comparisons of active TB
with LTBI, as well as active TB with healthy controls. Hsa-miR-
661 was up-regulated in comparisons of healthy controls with
active TB, as well as healthy controls with LTBI.
The multi-dimensional scaling generated by BRB Arraytools to
visualize the relationships between the 15 samples based on the
expression patterns of 17 miRNAs showed the active TB group
were located in a different quadrant from the major group of non-
active TB, which were composed by 4 latent TB and 3 healthy
controls (Figure 2A). Only minor differences existed between
latent and healthy controls. This revealed a discriminative pattern
between active TB versus latent TB or healthy controls.
Hierarchical clustering of the expression profiles of 17 miRNAs
also showed that individuals with active TB clustered indepen-
dently of individuals with LTBI or healthy controls (Figure 2B).
This difference between active and non-active TB groups was
mainly due to the induced expression of hsa-miR-365, hsa-miR-
223 and hsa-miR-302a, hsa-miR-486-5p, hsa-miR-144 and hsa-
miR-451, hsa-miR-21* and hsa-miR-424 in active TB patients.
Interestingly, 5 of the miRNAs (hsa-miR-365, hsa-miR-223 and
hsa-miR-144, hsa-miR-451, hsa-miR-424) were highly expressed
in PBMCs and their expression in 3 groups was confirmed by
qPCR. Meanwhile, the LTBI group was divided into 2 sub-
clusters; 2/6 had an expression profile similar to the expression
profile of the active TB group, and 4/6 clustered with healthy
controls. This finding indicates there may be different stages of
latency as it progresses to active disease Thus, by using 17
miRNAs, we identified a gene expression pattern or profile that
discriminates between active TB versus healthy controls with or
without M. tuberculosis infection.
To validate the microarray data, we used a SYBR-Green
miRNA real-time qPCR analysis of miRNAs from PBMCs from
23 patients with active TB, 23 subjects with LTBI, and 15 healthy
controls (Fig. 3). It should be noted that the expression intensities
of some miRNAs (e.g. hsa-miR-500) in our microarray chip were
just passed the threshold of detection; the low expressions of these
miRNAs in PBMCs may lead to a poor reproducibility of RT
PCR. Thus, in order to confirm our microarray data, we first
classified all the 17 miRNAs into 2 groups based on expression
values in PBMCs (reflected by mean of intensities in microarray).
Those miRNA with mean of intensities in microarray .10 were
classed to group 1, the rest miRNA Mean of intensities in
microarray ,10 were set as group 2 (Table S3).We picked 5
miRNAs from group 1; 3 miRNAs from group 2 representatively
to perform the RT PCR confirmation. The expression profiles of
the active TB and LTBI groups were statistically different for
miRNAs from group 1: hsa-miR-144 (P,0.05), hsa-miR-424
(P,0.01), hsa-miR-451(P,0.05), hsa-miR-223 (P,0.05), and hsa-
miR-365 (P,0.05). We observed that hsa-miR-424 and hsa-miR-
365 also exhibited increased expression levels in samples from
active TB versus healthy control groups (P,0.05). Our results
were similar to those obtained in the microarray assay. Although
most of the highly-expressed miRNAs in PBMCs showed
significantly different expression levels between active TB and
LTBI or healthy controls, not all microarray results could be
confirmed by RT PCR. Microarray analysis and real-time PCR
are two methods with different sensitivities and specificities, which
might explain why target miRNAs at low levels could not always
be detected by both methods [28].
Construction of MiRNA-Gene-Network
The ultimate goal of our project is to test the hypothesis that the
unique miRNA profiles and their target genes are associated with
the progression of infection with M. tuberculosis from latent TB to
active disease. Thus, we focused on miRNAs that are differentially
expressed between active and latent TB. A previous study
illustrated that there are alternated gene expression profiles in
PBMCs between these 2 groups [10]. Based on our microarray
data, several transcripts were negatively correlated with their
predicted or validated miRNA targets, this revealed the existence
miRNA Expression during M. tuberculosis Infection
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25832Figure 1. Unsupervised hierarchical clustering of the expression of 451 miRNAs. The tree was generated by unsupervised hierarchical
clustering of PBMC miRNA profiles for patients with active TB, subjects with LTBI, and healthy controls. MiRNAs with 2-fold up- or down-expression
compared with the median intensity across all samples and differential expression values greater than 10% of all samples were selected for
unsupervised analysis (n=415 miRNAs). Sample clusters can be compared with the clinical parameters displayed in blocks underneath each profile. A
key is provided at the bottom of the figure. Subjects’ clinical status is indicated as follows: patients with active TB are indicated by red rectangles;
subjects with LTBI by blue rectangles; and healthy controls by black rectangles. Age is indicated as: subjects between 15–24 years old are indicated by
olive green rectangles; subjects 25–34 years old by brown rectangles; subjects 35–44 years old by purple rectangles; and subjects 45–54 years old by
khaki rectangles. Females are indicated by hoar rectangles and males by darkish rectangles.
doi:10.1371/journal.pone.0025832.g001
miRNA Expression during M. tuberculosis Infection
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25832of a miRNA-Gene regulatory network in the transition from latent
to active TB. To identify the putative functional modules, we
constructed the MiRNA-Gene-Network (Fig. 4) based on the data
sets consisting of miRNA–target gene binding information and
expression profiles of miRNAs and mRNAs [29]. We used the
previously published mRNAs expression profiles from another
study of samples from active TB and LTBI participants in the
Gene Expression Omnibus (GEO) public database (www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE6112) [10]. We used
this published report because their study, like the present study,
used PBMCs in their RNA microarray assay.
We first performed an F-test between the Active TB and LTBI
groups using a P-value,0.05 in order to select all the potential
miRNAs expressed differentially. This test yielded a list of 17
miRNAs (Table 2) differentially expressed between these two
groups. A total of 3010 target genes (Table S4) for these 17
miRNAs (taken from the TargetScan Database www.targetscan.
org/) and their expression profiles were then imputed into the
Figure 2. Multi-dimensional scaling of the relationships and unsupervised hierarchical clustering based on the 17 miRNAs
expression pattern. A. Multi-dimensional scaling generated by BRB Arraytools of the relationships between the 15 samples based on the 17
miRNAs expression pattern. Red dot, active TB; Blue dot, latent TB; Black dot, healthy controls. B. The tree generated by unsupervised hierarchical
clustering (Pearson’s correlation, average linkage) of 15 samples (columns) and 17 miRNAs differentially expressed among the 3 groups predicted by
using the SVM method. Sample clusters can be compared with the clinical parameters displayed in blocks underneath each profile. A key is provided
at the bottom of the figure. Subjects’ clinical status is indicated as follows: patients with active TB are indicated by red rectangles; subjects with LTBI
by blue rectangles; and healthy controls by black rectangles. Age is indicated as: subjects between 15–24 years old are indicated by olive green
rectangles; subjects 25–34 years old by brown rectangles; subjects 35–44 years old by purple rectangles; and subjects 45–54 years old by khaki
rectangles. Females are indicated by hoar rectangles and males by darkish rectangles.
doi:10.1371/journal.pone.0025832.g002
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Methods). This method yielded a list of 12 miRNAs and 111
target genes with negatively correlated expression profiles (Table
S5). There were no detectable correlations between hsa-miR-451,
hsa-miR-342-5p and their target genes, which may be due to the
small quantity of target genes for these 2 miRNAs in database
(Table 2). Also we failed to retrieve the predicted or validated
target genes for 3 miRNAs (hsa-miR-21*, hsa-miR-130b* and hsa-
miR-550*) from the database. These 5 miRNAs were therefore
absent in the network. Of the 12 miRNAs in the network, 3 were
down-regulated in active TB, namely hsa-miR-155, hsa-miR-181b
and hsa-548b-3p. The other 9 miRNAs exhibited increased
expression in active TB. Hsa-miR-424 had the highest degree of
regulation in the MiRNA-Gene-Network; 37 target genes were
down-regulated in the mRNA expression profiles, followed by hsa-
miR-144 with 23 target genes and hsa-miR-302a, hsa-miR-181b
and hsa-520d-3p, both had 20 target genes in the network. Hsa-
miR-548b-3p and hsa-miR-640 showed the minimum degree of
regulation, with only 3 and 4 target genes included in the network.
Regarding the 111 genes, most of them (78 in 111) were
targeted by only one miRNA in the network (e.g. BCL2 was only
targeted by hsa-miR-424). The rest 33 genes were regulated by
multi-miRNAs: 14 genes were regulated by 2 miRNAs (e.g.
CEP68 was targeted by hsa-miR-424 and hsa-miR-223), and 13
genes were regulated by 3 miRNAs.. MYBL1 (v-myb myeloblas-
tosis viral oncogene homolog (avian)-like 1) and PDCD4
(programmed cell death 4) were regulated by 5 miRNAs (the
highest degree of regulation in the network), followed by BCL7A
(B-cell CLL/lymphoma 7A), CUL3 (cullin 3), FOXO1 (forkhead
box O1), and KIF3B (kinesin family member 3B) which were
regulated by 4 miRNAs in the network. Analysis of the Gene
Ontology (GO), a database based on molecular functions (Fig
S2A), and the Kyoto Encyclopedia of Genes and Genomes
(KEGG), a regulatory pathway database (Fig. S2B) for these 111
genes showed that most encoded proteins with transcription
regulator activity and protein binding functions were involved in
cellular growth, movement, and proliferation, such as focal
adhesion, MAPK signaling, Wnt signaling, insulin signaling,
Figure 3. Quantitative PCR (qPCR) validation of miRNA expression levels in samples from the active tuberculosis (TB) group versus
the latent tuberculosis infection (LTBI) groups. We confirmed the gene expression levels of miRNAs using real-time qPCR. We analyzed the
expression of 7 miRNAs (hsa-miR-223, hsa-miR-365 hsa-miR-424, and hsa-miR-451, hsa-miR-144, hsa-miR-500 and hsa-miR-21*) selected from the
microarray data by qPCR. The 2
2DDCT method was used to normalize the relative gene expression data in the qPCR assay. U6 snRNA was set as the
reference gene. The miRNA expression value in one subject with LTBI was normalized to 1. Statistical analysis was performed using the unpaired t-
test. ** P,0.01, * P,0.05, NS: not significant.
doi:10.1371/journal.pone.0025832.g003
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suggest that the miRNAs may regulate MTB infection by affecting
the development of immune cells.
Discussion
Our understanding the mechanisms of the transition from latent
infection to active TB remains incomplete [3]. Multiple host
factors are involved in this complex process. Herein, we focused on
miRNAs, a class of ,22-nucleotide short non-coding RNAs that
play key roles in fundamental cellular processes. The miRNA
registry currently contains ,1,000 human miRNAs sequences,
which target about 60% of mammalian genes. Our microarray
chip contains nearly 90% of these miRNAs. The expression profile
of these miRNAs showed high variability between individuals, and
was independent of their age, gender, or clinical phenotype.
However, we were able to distinguish the expression profile of the
active TB group from the expression profile of the latent TB group
using a 17-miRNA signature that was predicted by the SVM
method. The molecular classification obtained through hierarchi-
cal clustering of these 17 miRNAs showed a discriminative pattern
between active TB versus healthy controls with or without M. TB
infection. Two LTBI subjects outlying the non active TB cluster
and clustering together with active TB patients. A previous study
identified a 393-transcript signature in whole blood cells that
would discriminate between the different groups, and also
reported that 10–25% of the patients with LTBI clustered with
patients with active TB [12]. This may indicate there are different
stages of LTBI, and LTBI is in fact a spectrum of responses to TB
infection, ranging from individuals who have completely cleared
the infection to individuals who are incubating actively
replicating bacteria in the absence of clinical symptoms [3].
Because this complex process is associated with changes in the
host’s immune response, one would expect differential expression
of some genes or miRNAs. Unfortunately, we currently lack a
‘‘gold standard’’ for discriminating the different stages of latent
TB infection, which has made it very difficult to determine
whether the expression of a genes or miRNAs could reflect the
spectrum of responses to TB infection in different stages of latent
infection.
We focused on the miRNAs that were differently expressed in
active versus latent TB, in order to identify miRNAs that might be
Figure 4. MiRNA-Gene-Network for the transition from latent to active tuberculosis. The MiRNA-Gene-Network was built using the gene
expression data and the predicted interactions in the TargetScan miRNA database. The mRNA profile was obtained from previously published studies
[10]. miRNA–mRNA modules obtained via population-based probabilistic learning was used to determine the interactions in the network (Materials
and Methods). Circles represent genes and squares represent miRNAs; their relationship is represented by one edge. The center of the network
represents the degree (i.e., the interaction of one miRNA with the genes around and the interaction of one gene with the miRNAs around. The key
miRNAs and genes in the network always have the highest degrees.
doi:10.1371/journal.pone.0025832.g004
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17 miRNAs that were differentially expressed. The majority (12
out of 17 miRNAs) were up-regulated in patients with active TB.
Among these miRNAs, hsa-miR-223, hsa-miR-424, and hsa-miR-
451 and hsa-miR-144 were highly expressed in PBMCs compared
to other miRNAs. Interestingly, these 4 miRNAs are also involved
in the hematopoietic differentiation process. Previous studies using
a miR-223-knockout mouse showed an increased proration of
granulocytes, which are morphologically hypermature and
hypersensitive to activating stimuli, and have more fungicidal
activity [31]. Expression of miR-424 is induced during monocyte-
macrophage differentiation, and miR-424 subsequently down-
regulates expression of the transcription factor NFI-A78 [32].
Another study showed that miR-424 promotes monocytic
differentiation through combinatorial regulation with miR-155,
miR-222, and miR-503 [33]. MiR-451, with its cluster miR144, is
required for erythroid differentiation and homeostasis [34]. The
increased expression of these miRNAs in active TB may lead to
the changes in immune cell profile and the alterations of the host
immune response during MTB infection. Although we did not
perform a comparative phenotypic assay of cellular composition in
our samples, several studies found a related phenotype in active
TB patients. For example, a previous study that used whole-
genome transcriptional profiling revealed altered gene expression
profiles in different cell types, such as macrophages and NK cells,
in samples from active and latent TB [11]. Studies have also
shown an increase in the proportion of CD14+CD16+ inflamma-
tory monocytes and a decrease in the proportion of CD4+ T cells,
CD8+ T cells, and B cells in blood cells of patients with active TB
[12]. However, it is still unknown whether this alteration of cellular
composition and related gene expression in active TB patients is
regulated by miRNAs.
A previous study that used PBMCs to elucidate whole genome
expression profile differences between latent and active TB found
that 407 genes were upregulated and 364 genes were down
regulated in active TB (RVM-T test with a P,0.05) [11]. Among
these 771 genes, 111 were targeted by the 12 miRNAs
differentially expressed in our microarray assay. It should be
noted that 6/7 of affected genes during active TB are not targeted
by our identified miRNAs, including some genes with highest
degree of differential expression between active TB and latent TB
such as CD64, LTF and RAB33A, these genes may be targeted by
some miRNAs yet to be identified, also there may be other post-
transcriptional regulation such as RNA binding proteins .The
miRNA-Gene –Network for these 12 miRNAs and 111 genes
reveals the high regulatory role of miR-424, which targets 37 genes
in the network. Most of miR-424 target genes, such as BACH2,
BCL2, BCL7A, and FOXO1, are involved in cellular differenti-
ation and development. For example, the transcription factor
BACH2, together with other factors such as BLIMP1 appears to
constitute a transcriptional regulatory network for the differenti-
ation of B cells to plasma cell [35]. The specific function of BCL7A
has not yet been determined, however, it may play a role in T -cell
lymphoma [36]. Both BACH2 and BCL7A have been targeted by
multiple miRNAs in the network. Therefore, we hypothesize the
depressed expression level of these 2 genes by multiple miRNAs
such as hsa-miR-223 and hsa-miR-424 may lead to a disorder in
the proportions of T cells and B cells in active TB patients, which
may disturb the delicate balance of immune control in MTB
infection. Bcl-2 is the founding member of the Bcl-2 family of
apoptosis regulator proteins encoded by the BCL2 gene, which has
been supported a role for decreased apoptosis in the pathogenesis
of cancer [37]. Previous studies showed that apoptosis is an innate
defense function of macrophages against MTB infection. One
Table 2. Differently expressed miRNAs in the samples from study participants with active tuberculosis (TB) versus latent
tuberculosis infection (LTBI).
Geom mean of intensities in
miRNA
active
TB (n=6)
latent TB
(n=6)
Fold-
change
Parametric
p-value
Chromosomal
location
No. Target Genes in
TargetScan Database
No. Target Genes
in the Network
hsa-miR-130b* 1.05 3.15 0.33 0.0004416 22q11.21 NA NA
hsa-miR-223 9225.58 5243.09 1.76 0.0005922 Xq12 207 10
hsa-miR-424 49.49 15.18 3.26 0.0009967 Xq26.3 984 37
hsa-miR-302a 2.73 1.14 2.41 0.0042495 4q25 616 20
hsa-miR-21* 4.05 1.35 2.99 0.0046189 17q23.1 NA NA
hsa-miR-520d-3p 3.25 1.47 2.21 0.0066037 19q13.42 616 20
hsa-miR-486-5p 105.78 31.62 3.35 0.0083258 8p11.21 111 6
hsa-miR-451 2514.81 596.91 4.21 0.0093827 17q11.2 14 0
hsa-miR-342-5p 37.32 87.84 0.42 0.0183201 14q32.2 65 0
hsa-miR-550* 2.36 1.18 2 0.0275742 7p14.3 NA NA
hsa-miR-421 1.94 1.09 1.78 0.0281778 Xq13.2 276 8
hsa-miR-640 1.84 1.07 1.72 0.0289444 19p13.11 110 4
hsa-miR-144 27.22 3.39 8.04 0.0355072 17q11.2 661 23
hsa-miR-155 48.24 95.07 0.51 0.0438122 21q21.3 284 11
hsa-miR-181b 18.25 32.93 0.55 0.044274 1q32.1 904 20
hsa-miR-329 2.69 1.33 2.02 0.0446126 14q32.31 225 9
hsa-miR-548b-3p 1.05 2.1 0.5 0.045977 6q22.31 163 3
NA None of the target genes for these miRNAs were previously registered in the TargetScan database.
doi:10.1371/journal.pone.0025832.t002
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stimulate the macrophage to undergo apoptosis, which results in
a ‘cellular corpse’ with an impermeable envelope that prevents
bacteria from escaping. In contrast, virulent mycobacteria caused
macrophage death by a process that proceeds to necrosis, which
produces a permeable cell membrane that enables bacteria to
escape and spread [38,39]. Another study also assumed that
virulent mycobacteria are able to inhibit apoptosis by altering the
BCL2 pathway [40]. It is necessary to clarify whether the inhibited
expression of BCL2 by miRNAs results in the alternative forms of
cell death and induces the spreading of MTB in active TB patients.
Previous studies used whole-genome transcriptional profiling to
understand the host response to MTB infection and found some
potential signatures in the development of the disease [10, 11, and
12]. However, limitations of the microarray methods used in these
studies led to the dismissal of some unknown transcripts such as
miRNA. We report herein the changes in miRNAs expression
profiles associated with the transition from latent to active TB. We
identified specific miRNAs that were differentially expressed
among active TB, latent TB and healthy controls. Our miRNAs
microarray results show that these small non–coding RNAs may
potentially be used to discriminate between active TB disease and
latent TB infection. Our results increase the understanding of the
molecular basis of LTBI, and suggest that miRNAs expression
may play an important role in the pathogenesis of this infectious
disease by controlling related gene expression. In addition, the
putative miRNA targets provide new tools to better characterize
LTBI. Further testing and validation are needed to determine
whether miRNAs are useful markers, and whether they identify
progression from LTBI to active disease and response to therapy.
Materials and Methods
Ethics statement
The study was reviewed and approved by the local ethics
committee (Shanghai Public Health Clinical Centre). Written
informed consent was obtained from participants prior to their
enrollment in the study.
Patient selection and PBMC isolation
Patients were recruited and enrolled at the Shanghai Public
Health Clinical Centre (Shanghai, China) from December 2008
through May 2009. The demographic and clinical characteristics
of the 29 patients with active TB, the 29 subjects with LTBI, and
the 18 healthy controls are summarized in Table 1. The diagnosis
of active TB was based on clinical presentation, chest radiography,
and acid-fast stain of sputum smear. Lymph node TB was
diagnosed by microscopy of lymph fragments from fine needle
aspiration. Renal TB was diagnosed by microscopy of urinary
analysis, type B ultrasonography, and computerized tomography.
All of the patients were HIV negative, as diagnosed by the Livzon
Anti-HIV1/2 EIA Kit (Livzon Pharmaceutical Group Inc.,
Guangdong, China). Additional tests were also performed to
detect hepatitis B virus (HBV) and hepatitis C virus (HCV) using
the Abbott AxSYM anti-HBsAg and HCV 3.0 antibody assay kit
(Abbott Laboratories, Illinois) to exclude HBV- and HCV-positive
patients (these two diseases are highly prevalent in China). Patients
with a history of diabetes were also excluded because diabetes
could increase the risk of active TB. Peripheral venous blood was
drawn from study participants, prior to the initiation of any anti-
TB treatment. Study participants with LTBI and healthy controls
were recruited from the staff at the Shanghai Public Health
Clinical Centre. Potential study participants were excluded if they
had a prior history of TB or another infectious disease. Tuberculin
skin testing (TST) and interferon-gamma release assay (IGRA) (T-
SPOTH.TB, Oxford Immunuotec, Oxfordshire, U.K.) results were
used to distinguish between the two groups. The LTBI group was
TST-positive (TST.10 mm) and IGRA-positive while the healthy
controls were TST-negative (TST,5 mm) and IGRA-negative.
Three donors with TST-positive results IGRA-negative results
were also included as healthy controls. The active TB group
included patients with pulmonary TB (n=27), renal TB (n=1),
and TB of the lymph node (N=1); 28 of these patients were
receiving TB treatment for the first time, and 1 was a case of
retreatment TB. Patients with a positive sputum smear test result
were diagnosed with pulmonary TB, and TST was not performed
on them. There was no significant difference in age between the
different groups (P-value=0.412, one-way ANOVA test). How-
ever, there was a high proportion of males among patients with
active TB and a high proportion of females among healthy
controls., and the overall test for differences in gender was
statistically significant (P-value=0.0012, chi-square test).Periph-
eral venous blood (10 ml) was drawn from each subject and
PBMCs were isolated on Ficoll gradients (GE Health Care, Little
Chalfont, U.K.). PBMCs were immediately mixed with the miR
VanaTM miRNA isolation kit Lysis Buffer (Ambion, Inc., Austin,
Texas, USA) and frozen at 280uC until RNA was extracted. The
separate RNA samples from a randomly chosen subgroup of 6
patients with active TB, 6 donors with LTBI, and 3 healthy
controls (total of 15 biologically independent samples) were used in
the microarray assay (see Table S1). The rest of the samples were
used for real-time qPCR confirmation.
RNA extraction and quantitation
Total RNA was extracted using the miR VanaTM miRNA
isolation kit (Ambion Inc .Austin, Tx,USA) according to the
manufacturer’s instructions. RNA quantity and quality was
assessed using the Nanodrop 2000 (Thermo Fisher Scientific,
MA,USA) and Agilent 2100 bioanalyzer systems (Agilent Tech-
nologies). Samples with a RNA Integrity Number above 7 were
used in the study.
MiRNA microarray hybridization
MiRNA microarray assays were performed using the Agilent
Human miRNA microarray platform (version 3, Agilent Tech-
nologies) at Shanghai Biochip Co., Ltd. (Shanghai, China). The
microarray contains probes for 866 human and 89 human viral
miRNAs from the Sanger miRBase (release 12.0, Sanger Institute,
city, UK). Total RNA (100 ng) obtained from samples was labeled
via Cy3 incorporation. Microarray slides were scanned by using
the XDR Scan (PMT100, PMT5). Labeling and hybridization
were performed according to the protocol in the Agilent miRNA
microarray system.
Microarray Data Submission
Microarray data submission for human arrays is MIAME-
compliant. The raw data was submitted to the Gene Expression
Omnibus (GEO) database, and is available under the following
accession numbers: GSE29190; GPL10850; GSM72294–
GSM722308.
Computational analysis of miRNA microarray data
The microarray image information was converted into spot
intensity values using the Scanner Control Software Rev. 7.0
(Agilent Technologies). The signal (after background subtraction)
was exported directly into the GeneSpring GX9.0 software
(Agilent Technologies) for normalization. The mean normalized
miRNA Expression during M. tuberculosis Infection
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e25832signal from different groups was used for comparative expression
analysis by using the software package BRB-ArrayTools developed
by Dr. Richard Simon and the BRB-ArrayTools Development
Team (http://linus.nci.nih.gov/BRB-ArrayTools.html). Data
were filtered to exclude those miRNAs with expression values
less than 10% in all samples. The remaining miRNAs were then
filtered to select those having at least a 2-fold change in either
direction from the miRNA’s median intensity across all samples.-
After filtering, the data were then partitioned into 3 classes: Active
TB, LTBI, and Healthy Control. Using the ‘class comparison’
multivariate permutation test and after averaging dye-swapped
experiments, we identified genes that were differentially expressed
between the different groups. Statistical analysis for differential
expression was performed using random variance t-statistics for
each miRNA. Hierarchical clustering was performed with the
Pearson’s correlation for differentially expressed miRNAs. The
fold changes in the expression signals between different groups
were calculated from the normalized values.
Real-time qPCR analysis
miRNA real-time qPCR analysis was performed at CWBio.Co.,
Ltd. (Beijing, China). Briefly, the NEB E. coli poly (A) polymerase
was first used to add poly (A) tail to total RNA. Complementary
DNA was then synthesized by using the HiFi-MMLV reverse
transcriptase (CWbio.Co., Ltd) and miRNA specific reverse
transcription primers. SYBR Green (UltraSYBR Mixture,
CWbio.Co Ltd) uptake in double-stranded DNA was measured
using the Roche LightCyclerH 480 Real-Time PCR System. We
calculated 2
2DDCT and used this statistic to determine relative
gene expression. The reference gene was U6 snRNA.
MiRNA-Gene network construction
To build the MiRNA-Gene-Network, we determined the
relationship between miRNAs and genes by using their differential
expression values, and the interactions between miRNA and genes
in the TargetScan mRNA database. Briefly, published mRNAs
expression profiles of active TB and latent TB were downloaded
from the GEO public database (www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE6112).We used the RVM-T test
(P,0.05) to identify the differently expressed genes and miRNAs
from the gene expression profiles. The overlap between the genes
whose expression was induced and the target genes whose
expression was reduced by miRNA were then chosen to construct
the network based on the two respective expression values by using
the miRNA–mRNA modules via population-based probabilistic
learning methods [26,27]. The adjacency matrix of miRNA and
genes A=[ai, j] was created by using the attribute relationships
between genes and miRNAs, where ai,j represents the relationship
weight between gene i and miRNA j. In the MiRNA-Gene-
Network, circles represent genes and squares representing
miRNAs; their relationship is represented by one edge. The
center of the network represents the degree (i.e., the interaction of
one miRNA with the genes around, or the interaction of one gene
with the miRNAs around. The key miRNAs and genes in the
network always have the highest degrees.
Supporting Information
Figure S1 Prediction of 17 miRNAs differentially ex-
pressed among different groups by using support vector
machines (SMVs) method. The gene expression profiles of
three different groups of study participants (Active TB, Latent TB
and Healthy group) were first differentiated using a supervised
learning algorithm (binary tree classification). In Round 1, F-tests
were first performed between node 1 (Active TB VS Non Active
TB), node 3 (Healthy VS Non healthy), node 5 (Latent TB VS
Non latent TB). The Round 2, F-tests were then performed
between node 2 (Healthy VS Latent TB), node 4 (Active TB VS
Latent TB), node 6 (Active TB VS Healthy). Finally, the miRNAs
from both the Round 1 F test and the Round 2 F test were selected
and marked as the miRNAs that were differentially expressed
among different groups. miRNAs in red regarded those expressed
differentially between Active TB and Latent TB; miRNAs in green
regarded those expressed differentially between Active TB and
Healthy; miRNAs in blue regarded those expressed differentially
between Latent TB and Healthy; miRNAs in yellow regarded
those expressed differentially among the 3 groups. Parametric p-
value from all the F-test was ,0.01.
(TIF)
Figure S2 GO and KEGG annotations of 111 target
genes in the network. Enriched molecular functions of
differentially expressed genes based on GO classifications (A)
and KEGG pathways annotations (B) for genes targeted by
miRNAs that were differently expressed between the active and
latent TB groups. Functional annotation analysis was performed
with the help of the Database for Annotation, Visualization and
Integrated Discovery Bioinformatics Resources 2008 (http://
david.abcc.ncifcrf.gov). Individual genes can be found under
multiple GO/KEGG annotations. The percentages indicate the
number of genes sharing a certain GO/KEGG term relative to the
complete list of differentially expressed genes in both comparisons.
(TIF)
Table S1 Characteristics of tuberculosis patients, la-
tent TB infection and healthy control donors used for
miRNA microarray.
(DOC)
Table S2 38 miRNAs differently expressed among
active TB, latent TB, and healthy donors in at least
one comparison by univariate tests (P,0.01).
(XLS)
Table S3 17 miRNAs differently expressed in micro-
array profiles among active TB, latent TB, and healthy
donors by SVM prediction.
(DOC)
Table S4 3010 target genes (from TargetScan Database
www.targetscan.org/) of 17 miRNAs differently ex-
pressed between active tuberculosis (TB) and latent
tuberculosis infection (LTBI).
(XLS)
Table S5 12 miRNAs and their 111 target genes in the
network.
(XLS)
Acknowledgments
We appreciate all the patients and healthy controls who participated in
this research at the Shanghai Public Health Clinical Centre, Shanghai,
China. We thank Brent Dibble (NYU School of Medicine) for his help in
the English language editing of this paper.
Author Contributions
Conceived and designed the experiments: CW SY QG. Performed the
experiments: CW SY. Analyzed the data: CW SY GS. Contributed
reagents/materials/analysis tools: XT SL. Wrote the paper: CW ON
QG.
miRNA Expression during M. tuberculosis Infection
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25832References
1. World Health Organization (2009) WHO Report 2009: Global Tuberculosis
Control. Epidemiology, Strategy, Financing.
2. Kaufmann SH, McMichael AJ (2005) Annulling a dangerous liaison: vaccination
strategies against AIDS and tuberculosis. Nat Med 11: S33–44.
3. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, et al. (2009) The spectrum of
latent tuberculosis: rethinking the biology and intervention strategies. Nature
Reviews Microbiology 7: 845–855.
4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The
growing burden of tuberculosis - Global trends and interactions with the HIV
epidemic. Archives of Internal Medicine 163: 1009–1021.
5. Verver S, Warren RM, Munch Z, Vynnycky E, van Helden PD, et al. (2004)
Transmission of tuberculosis in a high incidence urban community in South
Africa. International Journal of Epidemiology 33: 351–357.
6. Selwyn PA (1993) Clinical Manifestations and Predictors of Disease Progression
in Drug-Users with Human-Immunodeficiency-Virus Infection (Vol 327, Pg
327, 1992). New England Journal of Medicine 328: 671–671.
7. Lin PL, Flynn JL (2010) Understanding latent tuberculosis: a moving target.
J Immunol 185: 15–22.
8. Casanova JL, Abel L (2002) Genetic dissection of immunity to mycobacteria: the
human model. Annu Rev Immunol 20: 581–620.
9. Chao MC, Rubin EJ (2010) Letting Sleeping dos Lie: Does Dormancy Play a
Role in Tuberculosis? Annual Review of Microbiology Vol 64, 2010 64:
293–311.
10. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, et al. (2007)
Candidate biomarkers for discrimination between infection and disease caused
by Mycobacterium tuberculosis. Journal of Molecular Medicine-Jmm 85:
613–621.
11. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, et al. (2011)
Human gene expression profiles of susceptibility and resistance in tuberculosis.
Genes and Immunity 12: 15–22.
12. Berry MPR, Graham CM, McNab FW, Xu ZH, Bloch SAA, et al. (2010) An
interferon-inducible neutrophil-driven blood transcriptional signature in human
tuberculosis. Nature 466: 973-U998.
13. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, et al. (2011) Dominant
TNF-alpha(+) Mycobacterium tuberculosis-specific CD4(+) T cell responses
discriminate between latent infection and active disease. Nature Medicine 17:
372-U174.
14. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
15. Coolen M, Bally-Cuif L (2009) MicroRNAs in brain development and
physiology. Current Opinion in Neurobiology 19: 461–470.
16. Ivey KN, Srivastava D (2010) MicroRNAs as Regulators of Differentiation and
Cell Fate Decisions. Cell Stem Cell 7: 36–41.
17. Bailey SG, Sanchez-Elsner T, Stephanou A, Cragg MS, Townsend PA (2010)
Regulating the genome surveillance system: miRNAs and the p53 super family.
Apoptosis 15: 541–552.
18. Dykxhoorn DM (2010) MicroRNAs and Metastasis: Little RNAs Go a Long
Way. Cancer Research 70: 6401–6406.
19. Skalsky RL, Cullen BR (2010) Viruses, microRNAs, and Host Interactions.
Annual Review of Microbiology Vol 64, 2010 64: 123–141.
20. Iorio MV, Croce CM (2009) MicroRNAs in Cancer: Small Molecules With a
Huge Impact. Journal of Clinical Oncology 27: 5848–5856.
21. Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD (2008)
MicroRNAs: new regulators of immune cell development and function. Nature
Immunology 9: 839–845.
22. Lodish HF, Zhou BY, Liu G, Chen CZ (2008) Micromanagement of the
immune system by microRNAs (vol 8, pg 120, 2008). Nature Reviews
Immunology 8: 238–238.
23. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al.
(2009) Therapeutic silencing of microRNA-122 in primates with chronic
hepatitis C virus infection. Science 327: 198–201.
24. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA
expression profiles classify human cancers. Nature 435(7043): 834–8.
25. Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, et al. (2009)
Genomic transcriptional profiling identifies a candidate blood biomarker
signature for the diagnosis of septicemic melioidosis. Genome Biology 10: R 127.
26. Zhao Y, Simon R (2008) BRB-ArrayTools Data Archive for human cancer gene
expression: a unique and efficient data sharing resource. Cancer Inform 6: 9–15.
27. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, et al. (2009) Differential
MicroRNA Expression Between Hepatitis B and Hepatitis C Leading Disease
Progression to Hepatocellular Carcinoma. Hepatology 49: 1098–1112.
28. Wang B, Howel P, Bruheim S, Ju J, Owen LB, et al. (2011) Systematic
Evaluation of Three microRNA Profiling Platforms: Microarray, Beads Array,
and Quantitative Real-Time PCR Array. PLoS ONE 6(2): e17167. doi:10.1371.
29. Shalgi R, Lieber D, Oren M, Pilpel Y (2007) Global and local architecture of the
mammalian microRNA-transcription factor regulatory network. Plos Compu-
tational Biology 3: 1291–1304.
30. Joung JG, Hwang KB, Nam JW, Kim SJ, Zhang BT (2007) Discovery of
microRNA-mRNA modules via population-based probabilistic learning. Bioin-
formatics 23: 1141–1147.
31. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, et al. (2008)
Regulation of progenitor cell proliferation and granulocyte function by
microRNA-223. Nature 451: 1125-U1111.
32. Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis FG, et al. (2007)
The interplay between the master transcription factor PU.1 and miR-424
regulates human monocyte/macrophage differentiation. Proceedings of the
National Academy of Sciences of the United States of America 104:
19849–19854.
33. Forrest ARR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N,
et al. (2010) Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503,
promotes monocytic differentiation through combinatorial regulation. Leukemia
24: 460–466.
34. Rasmussen KD, Simmini S, Abreu-Goodger C, Bartonicek N, Di Giacomo M,
et al. (2010) The miR-144/451 locus is required for erythroid homeostasis.
Journal of Experimental Medicine 207: 1351–1358.
35. Igarashi K, Ochiai K, Muto A (2007) Architecture and dynamics of the
transcription factor network that regulates B-to-plasma cell differentiation.
Journal of Biochemistry 141: 783–789.
36. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S,
et al. (2005) Epigenetic profiling of cutaneous T-cell lymphoma: Promoter
hypermethylation of multiple tumor suppressor genes including BCL7a,
PTPRG, and p73. Journal of Clinical Oncology 23: 3886–3896.
37. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, et al. (2007)
Overexpression of nucleolin in chronic lymphocytic leukemia cells induces
stabilization of bcl2 mRNA. Blood 109: 3069–3075.
38. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, et al. (2011) Apoptosis
is an innate defense function of macrophages against Mycobacterium
tuberculosis. Mucosal Immunology 4: 279–287.
39. Gan H, Lee J, Ren F, Chen M, Kornfeld H, et al. (2008) Mycobacterium
tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation
on infected macrophages to maintain virulence. Nat Immunol 9(10): 1189–97.
40. Zhang J, Jiang R, Takayama H, Tanaka Y (2005) Survival of virulent
Mycobacterium tuberculosis involves preventing apoptosis induced by Bcl-2
upregulation and release resulting from necrosis in J774 macrophages. Microbiol
Immunol 49: 845–852.
miRNA Expression during M. tuberculosis Infection
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e25832